This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
HeadlineMEDTECH

AI Auscultation Analysis Headphone StethoAI Receives FDA Approval: Detect Heart and Lung Anomalies via Headphone Microphone

Medical AI company HeartSound releases StethoAI headphone app that uses standard noise-canceling headphone microphones to capture and analyze cardiopulmonary sounds, 96% sensitivity for heart murmurs in 4,700-patient clinical trial, FDA Class II approved

The Stethoscope Has Been Installed in Your Headphones

The stethoscope was invented in 1816 and has barely changed in over 200 years. Doctors place a metal chest piece on the patient's chest, listen with their ears, and make judgments based on experience. This diagnostic method relies heavily on individual physician expertise, with inter-observer agreement at only 60%.

Medical AI company HeartSound aims to change this. StethoAI, released on March 19, is a mobile application that transforms standard noise-canceling headphones into an AI-assisted auscultation device.

Usage is remarkably simple: users place the headphone microphone on designated chest positions (the app provides AR-guided positioning), hold still for 15 seconds. StethoAI uses active noise cancellation to filter ambient noise, extracts clean cardiopulmonary sound signals, then analyzes them with an AI model.

"The key technological breakthrough is noise suppression," explained HeartSound CMO Dr. Sarah Kim. "Traditional auscultation requires a quiet clinical environment. Our algorithm can extract cardiopulmonary sound signals of clinical-grade quality even in noisy settings."

StethoAI's AI model was trained on over 5 million cardiopulmonary sound recordings covering more than 80 cardiopulmonary disease signatures. In a 4,700-patient clinical trial, the system achieved 96% sensitivity and 93% specificity for heart murmurs, and 94% sensitivity and 91% specificity for abnormal lung sounds.

Dr. Kim emphasized StethoAI's value in primary care: "Over 4 billion people worldwide lack access to specialist auscultation services. A pair of headphones and a smartphone can enable anyone to perform professional-grade cardiopulmonary screening."

The FDA classified StethoAI as a Class II medical device, meaning it can serve as an auxiliary screening tool but cannot replace final physician diagnosis. HeartSound has deployed StethoAI in 50 primary care clinics in India and Kenya, targeting 500 by end of 2030.

All cardiopulmonary sound data is analyzed locally on-device without cloud upload. HeartSound says the system design complies with HIPAA and GDPR standards.

StethoAI is priced at $29/year (personal) and $199/year (healthcare institution). HeartSound has completed a $35 million Series A round at a $280 million valuation.